^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SR16157

    i
    Other names: SR16157, HLX 801, NSC 732011
    Company:
    SRI International
    Drug class:
    Steroid receptor inhibitor, Estrogen receptor modulator
    Related drugs:
    9ms
    Development of a prognostic model for lung adenocarcinoma polarity-related genes and analysis of immune landscape. (PubMed, Biotechnol Appl Biochem)
    XAV-939, Fulvestrant, and SR16157 may have potential value in the clinical use of LUAD. We revealed the potential linkage between PRGs and LUAD prognosis, and the application of these prognostic factors in risk stratification and prognosis prediction of LUAD patients may be of great significance.
    Journal • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden)
    |
    fulvestrant • SR16157 • XAV-939